# LOTIS-2 (NCT03589469)

> Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03589469
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: ADC Therapeutics S.A.
- Conditions: Diffuse Large B-Cell Lymphoma Refractory; Diffuse Large B-cell Lymphoma Recurrent
- Interventions: Loncastuximab tesirine
- Enrollment: 145
- Primary outcome: Overall Response Rate (ORR)

## Commentary we found

- YouTube: 11
- Podcasts: 9
- X threads: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=lotis-2-nct03589469

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03589469", "email": "<work email>"}; the inbox owner confirms by the emailed link.